Navigation Links
Data From Anthera's Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions
Date:2/7/2008

SAN MATEO, Calif., Feb. 7 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that data from the Phase II trial of its novel secretory phospholipaseA2 inhibitor Varespladib (A-002) for the treatment of coronary heart disease will be presented as a late breaker at the 2008 American College of Cardiology 57th Annual Scientific Session on Monday, March 31, 2008 in Chicago, Illinois.

The Phase II trial known as PLASMA (Phospholipase Levels And Serological Markers of Atherosclerosis) was a multi-center, randomized, double-blind, placebo-controlled trial that enrolled approximately 400 patients with stable coronary heart disease in the U.S. and Ukraine. Subjects were randomized to receive one of four different doses of A-002 or placebo for up to eight weeks. Patients also received doctor-determined standard of care therapies. The primary endpoint was a reduction in secretory phospholipase A2 (sPLA2). The study also evaluated the effect of Varespladib on cholesterol levels (LDL-C, non-HDL and total cholesterol) as well as inflammation in patients with stable coronary heart disease.

PLASMA Late-Breaker Trial Data Presentation:

Date/Time: Monday, March 31 from 2:30-2:45pm.

Title/Author: Effects of a Selective Inhibitor of Secretory

Phospholipase A2 on Low Density Lipoproteins and Inflammatory Pathways,

Robert S. Rosenson, MD, Director, Lipoprotein Disorders and Clinical

Atherosclerosis Research, Division of Cardiovascular Medicine at the

University of Michigan, for the PLASMA Investigators.

Location: McCormick Place, Vista Room S406

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and a
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. New Studies Find Plasma Disc Decompression Effective for Contained Disc Herniation
2. PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade(TM)
3. Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study
4. Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program
5. Toxoplasma infection increases risk of schizophrenia, study suggests
6. New Heart Pump Shows Promise in Trial
7. Trial to Test Gene Therapy for Angina in Women
8. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
9. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. MDS Pharma Services Wins Award for Management of Global Malaria Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 17, 2014 Keep that sexy decolletage as ... the neck. , "The Face Whisperer Neck & Decollete ... Kathy Heshelow, founder of Sublime Beauty®. "It contains rich ingredients ... MSM and arnica." , A special ingredient is Argireline, known ... The rich anti-aging cream comes in an airless pump bottle, ...
(Date:9/16/2014)... Today, Zane Benefits, the #1 ... transitioning employees to individual health insurance. , ... Act (ACA) in full effect, many small and ... all of their employees towards individual health insurance. ... plans, coverage for pre-existing conditions, and premium tax ...
(Date:9/16/2014)... UWDress.com, the well-known wedding dress manufacturer and ... assortment online. Additionally, the firm has launched a ... big discounts now, up to 62 percent off. ... charming; it has won a lot of positive reviews ... is also providing big savings on many other items, ...
(Date:9/16/2014)... (September 16th, 2014; San Francisco) In a ... increasingly weighed against potential benefit, a Yale study ... or less-aggressive radiation procedures on elderly women with ... be presented at the 56th annual conference of ... Francisco. (Abstract 131: Evaluating National Practice in Radiotherapy ...
(Date:9/16/2014)... Recently, iFitDress.com, one of the most famous dress suppliers in ... gown collection. According to the company’s sales manager, all ... to 69% off) at present. Additionally, all the company’s old ... a frequent caller of your site. I like your products ... quite happy. All items are of good quality. I sincerely ...
Breaking Medicine News(10 mins):Health News:15% Off Face Whisperer® Neck & Decollete Cream Now from Sublime Beauty; Care For This Delicate Skin That Shows Age Quickly 2Health News:Zane Benefits Publishes New Information on Transitioning Employees to Individual Health Insurance 2Health News:New Elegant Evening Wear Assortment Released By UWDress.com 2Health News:iFitDress.com: One Shoulder Evening Gown Collection Unveiled Online 2
... between Uttar Pradesh Government Railway Police and Junior doctors ... Meerut by Meerut Nauchandi Express lead to injuring medicos ... the police personnel occupying the reserved seats of the ... seven state medical colleges for three days ordering enquiry ...
... appearing in the January 18 issue of The Journal of ... when adult neurons try to undergo division. This finding in ... development of the disease. ,"If you could ... from dying prematurely. This could be a fresh approach to ...
... are of the opinion that interstellar dust coming into our ... significance. The results have exceeded all expectations, according to Donald ... principal investigator, or lead scientist, for Stardust. ‘It's a huge ... ones, there are small ones’, he said. ...
... medicines will no longer be available to Canadians from supermarkets ... are aimed at preventing addicts from making crystal meth. //The ... be affected by the ban which will come into force ... sell about 15 medicines which are of the single ingredient ...
... masala and tobacco products near hospitals and educational institutions by the ... from beyond 500 meters from such institutions, according to the new ... that this is strictly adhered to. ,The youth ... product due its low price and easy availability. Children are also ...
... call to bedside phones cost higher than the call made ... charges levied on the bedside phones. // ... complaining of the bedside phone charges. ,The company ... the peak time costed around 49p per minute and at ...
Cached Medicine News:Health News:Dividing Nerve Cells Could Trigger Alzheimer's Disease 2Health News:Ofcom To Assess The Bedside Call Charges 2
(Date:9/16/2014)... Sept. 16, 2014  This report analyzes the worldwide markets ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Middle ... Rest of World. Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
(Date:9/16/2014)... Sept. 16, 2014  Denovo Biopharma, LLC, today ... oncology drug, from Eli Lilly and Company (NYSE: ... and commercialize enzastaurin globally, including transfer of all ... Lilly developed enzastaurin in a ... Phase 3 clinical trials for diffuse large B-cell ...
(Date:9/16/2014)... Resources Group finds that the rheumatoid arthritis (RA) disease-modifying antirheumatic drug ... billion in 2023 in the United States , ... Italy , Spain , the ... TNF-alpha inhibitors will remain the leading drug class in both sales ... constrained and patient shares will decline due to the uptake of ...
Breaking Medicine Technology:Global Digital Radiography Industry 2Global Digital Radiography Industry 3Global Digital Radiography Industry 4Global Digital Radiography Industry 5Global Digital Radiography Industry 6Global Digital Radiography Industry 7Global Digital Radiography Industry 8Global Digital Radiography Industry 9Global Digital Radiography Industry 10Global Digital Radiography Industry 11Global Digital Radiography Industry 12Global Digital Radiography Industry 13Global Digital Radiography Industry 14Global Digital Radiography Industry 15Global Digital Radiography Industry 16Global Digital Radiography Industry 17Global Digital Radiography Industry 18Global Digital Radiography Industry 19Global Digital Radiography Industry 20Global Digital Radiography Industry 21Global Digital Radiography Industry 22Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3
... KineMed Inc., a,pathway-based drug discovery and development ... of an investigational agent,to regenerate nerve cells in ... cognition and mood. The agent, part of a ... a behavioral test in a,preclinical model. The findings ...
... am ET, BEDMINSTER, N.J., Oct. 11 ... top-line results from,the company,s Phase 3 study of ... 83 patients with short bowel,syndrome (SBS) received either ... dose (0.10 mg/kg/day) or placebo. The,clinical efficacy endpoint ...
Cached Medicine Technology:KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 2KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 2Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 4Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 5Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 6Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 7
For the quantitative in vitro determination of Aspartate Aminotransferase (AST) in serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
Medicine Products: